Early immune reaction after reduced-intensity cord-blood transplantation for adult patients.
BACKGROUND
To investigate immune reactions after reduced-intensity cord-blood transplantation (RI-CBT).


METHODS
We reviewed medical records of 57 adult RI-CBT recipients. Preparative regimen comprised fludarabine, total-body irradiation, and either melphalan (n=51) or busulfan (n=6). Graft-versus-host disease (GvHD) prophylaxis was cyclosporine. PostRI-CBT immune reactions were classified according to time course: pre-engraftment immune reactions (PIR), engraftment syndrome (ES), and GvHD.


RESULTS
Forty-five patients achieved engraftment at a median of day 19. PIR was characterized by high-grade fever and weight gain and developed on a median of day 9 in 35 of the 45 evaluable patients, including 3 who did not achieve engraftment. PIR subsided spontaneously in 12 patients, whereas corticosteroids were required in the other 23. ES and grade I to IV acute GvHD developed in 36 and 29 patients, respectively. GvHD could not be distinguished from preceding PIR or ES in 10 patients. Causes of the 32 nonrelapse mortalities included GvHD (n=5) and PIR (n=1). There were no significant differences in relapse and nonrelapse deaths between patients with PIR and those without it (18% vs. 5%, and 60% vs. 65%, respectively).


CONCLUSIONS
Immune reactions after RI-CBT can be categorized into three distinct subtypes.
Kishi
Yukiko
Y
Hematopoietic Stem-cell Transplantation Unit, the National Cancer Center Hospital, Tokyo, Japan.
Kami
Masahiro
M
Miyakoshi
Shigesaburo
S
Kanda
Yoshinobu
Y
Murashige
Naoko
N
Teshima
Takanori
T
Kusumi
Eiji
E
Hara
Shigeo
S
Matsumura
Tomoko
T
Yuji
Koichiro
K
Masuoka
Kazuhiro
K
Wake
Atsushi
A
Morinaga
Shinichi
S
Kanemaru
Mineo
M
Hayashi
Tatsuyuki
T
Tanaka
Yuji
Y
Taniguchi
Shuichi
S
D000328:Adult; D000368:Aged; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous / Q000276:immunology; D014916:Whole-Body Irradiation
D007166:Immunosuppressive Agents